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ABSTRACT
We have developed a novel class of antisense
agents, RNA Lassos, which are capable of binding
to and circularizing around complementary target
RNAs. The RNA Lasso consists of a fixed sequence
derived from the hairpin ribozyme and an antisense
segment whose size and sequence can be varied to
base pair with accessible sites in the target RNA.
The ribozyme catalyzes self-processing of the 5’-
and 3’-ends of a transcribed Lasso precursor and
ligates the processed ends to produce a circular
RNA. The circular and linear forms of the self-
processed Lasso coexist in an equilibrium that is
dependent on both the Lasso sequence and the
solution conditions. Lassos form strong, noncova-
lent complexes with linear target RNAs and form
true topological linkages with circular targets.
Lasso complexes with linear RNA targets were
detected by denaturing gel electrophoresis and
were found to be more stable than ordinary RNA
duplexes. We show that expression of a fusion
mRNA consisting of a sequence from the murine
tumor necrosis factor-a (TNF-a) gene linked to luci-
ferase reporter can be specifically and effi-
ciently blocked by an anti-TNF Lasso. We also
show in cell culture experiments that Lassos
directed against Fas pre-mRNA were able to
induce a change in alternative splicing patterns.
INTRODUCTION
The speciﬁc inhibition of gene expression dependent on
base pairing between an inhibitor and its DNA or RNA
target has generated substantial interest, due to the
potential ability to target any sequence by applying the
simple rules of Watson–Crick recognition. Inhibitors of
this type, broadly referred to as antisense molecules,
have widely been used as tools for functional genomics
and target validation, and to some extent as drugs. They
can be classiﬁed into several groups according to their
various mechanisms of action: (i) DNA-based oligonu-
cleotides that recruit RNase H to degrade the target
RNA following formation of the DNA–RNA duplex,
including oligodeoxynucleotides (ODNs) that are either
unmodiﬁed or contain certain modiﬁcations such as
phosphorothioate and 20-ﬂuoro groups (1,2); (ii) steric
blockers, which do not induce target cleavage but block
expression of the target, including phosphorodiamidate
morpholino oligomers (PMOs), N30-P50 phosphorodiami-
dates, 20-O-methoxyethyl RNAs, locked nucleic acids
(LNA), and peptide nucleic acids (PNA) (3–7); (iii) unmo-
diﬁed antisense RNAs that can be expressed intracellu-
larly from appropriate vectors (8–13); (iv) catalytic
nucleic acids (ribozymes and deoxyribozymes) that can
hybridize to and cleave target RNAs (14,15); and (v)
short interfering RNAs (siRNAs) and short hairpin
RNAs (shRNAs), which cause cleavage of target RNAs
via the naturally existing mechanism of RNA interference
(RNAi) (16,17). Although the mechanisms of posttran-
scriptional gene silencing by si/shRNAs may involve
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these mechanisms have in common the hybridization of
antisense guide sequences with the complementary site in
target mRNA (18).
Here, we introduce a new type of antisense agent, the
RNA Lasso, which contains both a ribozyme, whose
sequence is constant (target-independent), and an anti-
sense sequence, whose size and sequence can be varied
to match accessible sites in the target RNA. This design
allows the Lasso to pair with a target RNA, intertwining
the two RNAs, and then to undergo self-ligation, result-
ing in circularization of the Lasso around the target.
The ribozyme chosen to provide self-circularization is
the hairpin ribozyme (HPR) because of its ability to cat-
alyze both cleavage and ligation of substrate RNAs eﬃ-
ciently. Lassos can be conveniently synthesized by in vitro
transcription, in which case cis-cleavage by the HPR
allows excision of the Lasso from a longer transcript by
trimming both the 50- and 30-ends of Lasso molecules. This
reaction creates ends that are substrates for a second HPR
reaction, ligation in cis, which results in circularization of
the molecule. The circular and linear Lasso forms exist in
equilibrium, the position of which depends on the Lasso
sequence and solution conditions. These processing reac-
tions can occur spontaneously when the Lasso is expressed
in cells.
In experiments using fragments of murine tumor necro-
sis factor (TNF-a) mRNA as targets, we show that Lassos
having the appropriate TNF-speciﬁc antisense sequences
can eﬃciently bind to and circularize around the target
without cleaving it. This sequence-speciﬁc binding leads
to the formation of complexes that are more stable than
ordinary RNA–RNA duplexes used as controls. We also
demonstrate that these anti-TNF Lassos can speciﬁcally
and eﬃciently block expression of a model TNF-
Luciferase reporter gene in an in vitro translation assay.
In addition, we show that Lassos targeting the intron–
exon junction of Fas receptor pre-mRNA are able to
alter the pattern of alternative splicing in cultured cells.
MATERIALS AND METHODS
Preparation of Lassos
Transcription templates for all Lassos were prepared in
two steps as described below using synthetic oligodeoxy-
nucleotides provided by IDT (Coralville, IA, USA). All
sequences are shown in the 50–30 direction if not otherwise
indicated.
ATR1. First, two synthetic oligodeoxynucleotides, par-
tially complementary at their 30-ends, TGACAGTCCTG
TCCGTATGACAGAGAAGTCAACCAGAGAAACAC
ACGTTGTGGTATATTACCTGGTCAAGAGAAG and
AAACAGGACGGTCAGTTCTCTTCAAGGGACAAG
GCTCGGGAAAAAAAGGAACAGGGAACTTCTCTT
GACCAGG, were annealed and ﬁlled in by the Klenow
fragment of DNA polymerase I (Promega, Madison, WI,
USA) to create a double-stranded DNA fragment. Then
two extended oligodeoxynucleotide primers, GGCTCGA
ATTCTAATACGACTCACTATAGGGTGACAGTCC
TGTCCG and AAACAGGACGGTCAGTTC, were used
to extend, add a T7 promoter sequence and amplify the
DNA fragment from the previous step by PCR using Taq
DNA polymerase (Promega).
ALR562-2. Two partially complementary oligodeoxynu-
cleotides, CGTCCGTATGACGAGAGAAGCCTACCA
GAGAAACACACGACGTAAGTCGTGGTACATTAC
CTGGTACAAGCCTT and GTTGTTGTTGTTGTTGT
TGTTCTCTTCAAGGGACAAGGCTTGTACCAGGTA
ATGTACCACGACTTACGTC, were annealed and ﬁlled
in using Klenow extension to create a double-stranded
DNA fragment. Then the two extended oligodeoxy-
nucleotide primers, TAATACGACTCACTATAGGGA
GGCTGTCCTCGTCCGTATGACGAGAGAAGC and
GACGAGGACAGCCTTGGTTGTTGTTGTTGTTGTT
GTTGTTGTTCTCTTC, were used to extend, add a T7
promoter sequence and amplify the DNA fragment from
the previous step by PCR.
FAS1, FAS2 and FAS3. In vitro transcription templates
encoding the anti-Fas Lassos were prepared similarly to
the anti-TNF Lassos. First, the pairs of partially overlap-
ping oligodeoxynucleotides (FAS 1-1 and FAS 1–2 for
Fas1; FAS 2–1 and FAS 2–2 for Fas2; and FAS 3–1
and FAS 3–2 for Fas 3) were annealed and ﬁlled in
using Klenow extension to create a double-stranded
DNA fragment. These fragments were simultaneously
extended, T7 promoter sequence added and ampliﬁed by
PCR using the following oligodeoxynucleotide primers:
FAS 1–3 and FAS 1–4 for Fas1; FAS 2–3 and FAS 2–4
for Fas2; FAS 3–3 and FAS 3–4 for Fas3. The sequences
of oligodeoxynucleotides described in this section are
shown below:
CGTCCGTATGACGAGAGAAGCGAACCAGAGA
AACACACGACGTAAGTCGTGGTACATTACCTGG
TAACGC (FAS1–1); TGTTGTTGTTGTTGTTGTTCA
ACCTACAGGATCCAGATCGCGTTACCAGGTAAT
GTACCACG (FAS 1–2); TAATACGACTCACTATA
GGGTCGCGGTCCTCGTCCGTATGACGAGAGAAG
(FAS 1–3); GACGAGGACCGCGAGTTGTTGTTGTT
GTTGTTGTTGTTGTTCAAC (FAS 1–4); CGTCCGTA
TGACGAGAGAAGTAGACCAGAGAAACACACGA
CGTAAGTCGTGGTACATTACCTGG (FAS 2–1); TGT
TGTTGTTGTTGTTCAATGTTCCAACCTACAGGAG
TTACCAGGTAATGTACCACGACTTACG (FAS 2–2);
TAATACGACTCACTATAGGGCTACAGTCCTCGTC
CGTATGACGAGAGAAG (FAS 2–3); GACGAGGA
CTGTAGTGTGTTGTTGTTGTTGTTGTTGTTCAAT
GTTCC (FAS 2–4); CGTCCGTATGACGAGAGAAGT
AGACCAGAGAAACACACGACGTAAGTCGTGGTA
CATTACCTGGTAACTTAG (FAS 3–1); GTTGTTG
TTGTTGTTGTTCCTACAGGATCCAGATCTAAGTT
ACCAGGTAATGTACCACGAC (FAS 3–2); TAATAC
GACTCACTATAGGGCTACAGTCCTCGTCCGTATG
ACGAGAGAAG(FAS3–3);GACGAGGACTGTAGGT
TGTTGTTGTTGTTGTTGTTGTTCCTAC (FAS 3–4).
Precursors to RNA Lassos were produced by in vitro
transcription with T7 RNA polymerase (Ambion, Austin,
TX, USA). The reaction was typically performed in 6mM
Mg
2+, 2mM spermidine–HCl, 40mM Tris–HCl (pH 7.5)
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ducts were treated with DNase I to degrade the transcrip-
tion template and desalted using a G-50 microspin column
pre-equilibrated with 1  TE buﬀer (Amersham/GE
Healthcare, Picataway, NJ, USA). Internally
32P-labeled
RNA Lassos were produced by addition of [a
32P]CTP to
the transcription reaction. The 50-end labeling of ATR1
self-processing products was performed posttranscription
with [g
32P]-ATP (Amersham) and T4 polynucleotide
kinase (NEB, Ipswich, MA, USA) by incubation at 378C
for 60min. The 30-end labeling was performed using
[
32P]pCp (Amersham) and T4 RNA ligase (NEB).
Purification of individuallinear and circular ATR1 forms
Following transcription of the ATR1 DNA template in
the presence of [a
32P]CTP, ATR1 was incubated for
30min in 50mM Tris–HCl, pH 7.5, 10mM MgCl2
(Lasso processing buﬀer, TM) to allow complete Lasso
self-processing. The Lasso species were separated by dena-
turing electrophoresis in polyacrylamide gels (d-PAGE)
containing 6% polyacrylamide, 8M urea and 0.5  TBE.
Prior to loading onto the gel, an equal volume of denatur-
ing loading buﬀer was added to the RNA (92% forma-
mide, 12mM EDTA, 0.1% xylene cyanol, 0.1%
bromophenol blue). Internally
32P-labeled ATR1 species
were visualized by autoradiography, and the bands corres-
ponding to the fastest (LL) and the slowest migrating (CL)
Lasso forms were excised from the gel. RNA was eluted
from the gel slices by crushing and soaking in 1  TE
buﬀer. It should be noted that use of standard RNA elu-
tion buﬀers may result in partial interconversion of the
HPR circular and linear forms (19). The eluted RNA
was puriﬁed using RNase-free Costar Spin-X columns
(Corning, NY, USA) and analyzed by 6% d-PAGE to
conﬁrm the purity of the individual Lasso species. It is
important to avoid ethanol precipitation of the individual
Lasso species because this procedure can also promote
HPR activity (19). To monitor conversion of linear
to circular ATR1 and vice versa, each eluted RNA was
incubated in TM buﬀer at 378C for 20min prior to
d-PAGE analysis.
Preparation ofRNA targets
TNF. The transcription template for the model TNF
RNA target was prepared by PCR using the primers
GAATTCGATTTAGGTGACACTATAGAAGAGCTC
TTCTGTCTACTGAACTTCGG and GTTGGACTCTG
AGCCATAATCC. The resulting DNA fragment, corre-
sponding to nucleotides 280–965 of the murine TNF-a
gene, was inserted into plasmid pGEM-4z (20), which
allows transcription of the insert from a SP6 promoter.
Nonradioactive TNF685 RNA (685nt) was produced by
in vitro transcription with SP6 RNA polymerase using the
MegaScript kit (Ambion) according to the manufacturer’s
protocol. Internally,
32P-labeled TNF685 RNA was pre-
pared by performing a small-scale transcription reaction
in the presence of [a
32P]-CTP. The eluted RNA was cen-
trifuged through RNase-free Spin-X columns to remove
gel fragments and analyzed by 6% d-PAGE to conﬁrm the
integrity and purity of the transcription products.
Circular RNA target, CMT. The transcription template
for the linear model target (LMT), which contains the
22-nt TNF target site, was prepared by annealing the
partially complementary DNA oligonucleotides, TAATA
CGACTCACTATAGGGTCAAAAGTTTCGACTGCAC
CTGACGAACAACAACAACAACAACAACAACGTTC
TCTTCAAGGGAC and TATGAGTTTCGACTGCACC
TGACGGTTGTTGTTGTTGTTGTTGTTGTTAGCCTT
GTCCCTTGAAGAGAACGTTGTTGTTGTTG, fol-
lowed by extension of 30-ends using the Klenow polymer-
ase. The resulting double-stranded DNA containing a T7
promoter was transcribed using T7 RNA polymerase to
produce LMT RNA. This RNA was treated with calf
intestinal alkaline phosphatase (CIAP, NEB) to remove
its 50-triphospate followed by phenol–chloroform extrac-
tion to remove CIAP, and ﬁnally precipitated by ethanol.
Then a single phosphate was added to the 50-end of LMT
by treating with [g
32P]-ATP and T4 polynucleotide kinase
followed by phenol–chloroform extraction and ethanol
precipitation. To convert to the circular form, LMT was
treated with T4 RNA ligase (NEB) for 4h at 168Ca s
described by Beaudry and Perreault (21). The ligation
product,
32P-labeled CMT, had a slower electrophoretic
mobility than LMT. CMT was puriﬁed using 9%
d-PAGE, eluted from the gel by crushing and soaking in
1  TE buﬀer. The eluted RNA was centrifuged through
RNase-free spin-X columns and precipitated by ethanol.
The circular nature of CMT was conﬁrmed by its
reduced gel mobility in comparison to the linear LMT
(22) as well as by partial alkaline-induced cleavage and
phosphatase treatment (23,24). Brieﬂy, 50-
32P-labeled
LMT and CMT labeled at its ligation site were ﬁrst incu-
bated with increasing amounts of NaOH (10–100mM) for
5min at 258C. An analysis of the cleavage products using
9% d-PAGE revealed that LMT generated a normal
ladder corresponding to cleavage products fragments dif-
fering by one nucleotide, while CMT generated a main
band comigrating with LMT with no intermediate bands
between these two forms. This pattern corresponds to cir-
cular RNA since each single cleavage produces linear RNA
molecules with various ends but the same length. In the
second assay, the
32P-labeled LMT and CMT were incu-
bated with or without CIAP at 378C for 10min and ana-
lyzed by 9% d-PAGE. As expected, 50-end labeled LMT
was dephosphorylated whereas the CMT retained its
32P-
label.
TNF22-Luc. The model target message TNF22-Luc was
constructed by inserting upstream of the luciferase trans-
lation start codon a T7 promoter followed by the 22-nt
TNF-a sequence that is complementary to the antisense
sequence of ATR1. This was accomplished by hybridiza-
tion of appropriate synthetic DNA to form the sequence
shown in Figure 6a ﬂanked by NcoI sites. This fragment
was digested by NcoI (Invitrogen, Carlsbad, CA, USA)
and inserted into the pGL3 Control Vector (Promega) at
its NcoI site using T4 DNA ligase (Invitrogen). The resul-
tant vector was cloned in DH5 bacterial cells and isolated
6754 Nucleic Acids Research, 2008, Vol. 36, No. 21using QIAprep columns (Qiagen). It was then linearized
by BamH1 (NEB) at the 30-end of the luciferase gene,
treated by proteinase K and puriﬁed by phenol–chloro-
form extraction and ethanol precipitation. The TNF22-
Luc mRNA (1923nt) was synthesized by in vitro transcrip-
tion of this linearized vector using the T7 Ribomax large-
scale RNA kit (Promega).
Pro-IL1 . The plasmid constructs and in vitro transcrip-
tion reaction used to generate proIL-1b mRNA for in vitro
translation experiments were done as described by Jobling
et al. (25).
Fas. A DNA fragment encoding the Fas RNA target
including the intron 5/exon 6 junction sequence
(Figure 7a) was generated by PCR from genomic DNA
of human Jurkat T lymphocytes (Promega) using a
forward primer to Intron 5, CATGGAATCATCAA
GGAATG (FasInt5-f), and a reverse primer to Exon 6,
GGTAAGAATGAGGCAAATC (FasEx6-r). The PCR-
ampliﬁed DNA fragment was cloned into the pCR2.1
vector downstream of the T7 promoter (to yield
pCR2.1-Fas) using the TA-cloning kit (Invitrogen).
Target Fas RNA (347nt) was transcribed in large scale
from the linearized pCR2.1-Fas vector using the T7
MEGAscript kit (Ambion). For in vitro binding studies,
internally
32P-labeled Fas target RNA was prepared by
performing a small-scale transcription in the presence
of [a
32P]-CTP.
In vitro bindingassays
Typically, 5ml reactions containing trace amounts of
internally
32P-labeled Lasso RNAs were incubated with
target RNAs (1.4mM) at 378C for 15–60min (as indicated)
in buﬀer containing 50mM Tris–HCl, pH7.5 plus either
10mM MgCl2 (TM buﬀer, +Mg condition) or 10mM
EDTA ( Mg condition). In addition, TM–formamide
buﬀer containing 50mM Tris–HCl, 10mM MgCl2, 20%
formamide has been used where indicated. For thermal
dissociation experiments, the complexes were subse-
quently postincubated for 2min at 50, 65, 80 or 958Ca s
indicated followed by immediate chilling on ice to prevent
rehybridization. Reactions were terminated by addition of
an equal volume of denaturing loading buﬀer containing
90% formamide, 12mM EDTA, 0.1% bromophenol blue,
0.1% xylene cyanol. Complexes were loaded onto 6%
polyacrylamide gels containing 8M urea and 0.5  TBE,
and were electrophoresed. The products were detected and
quantiﬁed using phosphorimager Molecular Imager FX
and Molecular Analyst 2.1 software for Macintosh
(Bio-Rad, Hercules, CA, USA).
In vitro translation assay
A total of 0.8mg TNF22-Luc target mRNA or pro-IL-1
mRNA (used as a nonspeciﬁc control) was preincubated
with 20-, 40-, 80- and 160-fold molar excess of Lasso
ATR1 over the target (yielding ﬁnal Lasso concentrations
of 1, 2, 4 and 8mM, respectively) as indicated in Figure 6b
for 1h at 378C in 10mM MgCl2, 50mM Tris–
acetate (pH 7.5). Equal aliquots of these solutions were
then mixed with FLEXI rabbit reticulocyte lysate transla-
tion system components (Promega). Following a 40min
incubation with rabbit reticulocyte lysate in the presence
of
35S-labeled methionine (Amersham/GE Healthcare),
the translation products were separated by nondenaturing
12% PAGE–SDS according to the manufacturer’s proto-
col. Products were detected by radiography. The autora-
diogram was scanned and translation levels of TNF-a
relative to pro-IL-1 were quantiﬁed by the program UN-
SCAN-IT Gel (Silk Scientiﬁc, Orem, UT, USA).
Splicingredirection experiments
Human Jurkat lymphocytes (E6-1 derivative, ATCC
#TIB-152) were transfected with the anti-Fas Lassos
using oligofectamine (Invitrogen). Total RNA from
 1.2 10
6 treated Jurkat cells was isolated by Trizol
(Invitrogen) according to the manufacturer’s protocol
24–48h after transfection. RT–PCR was performed on
the extracted total cellular RNA with Superscript II
reverse transcriptase (Invitrogen) using an anchored
oligo(dT)20 primer (Invitrogen) followed by 40 cycles of
PCR. A forward primer corresponding to nucleotides
410–430 (FasEx4-f, 50-CTACTGTATGTGAACACTGT
G-30) and a reverse primer corresponding to nucleotides
721–702 (FasEx9-r, 50-TCATGACTCCAGCAATAGTG-
30) were used in the PCR step. In a control PCR experi-
ment, b-actin sense primer corresponding to nucleotides
578–609 (50-ATCTGGCACCACACCTTCTACAATGA
GCTGCG-30) and antisense primer complementary to
nucleotides 1415–1384 (50-CGTCATACTCCTGCTT
GCTGATCCACATCTGC-30) were used as described
in Shiraki et al. (26). The resulting PCR-ampliﬁed DNA
fragments corresponding to full-length Fas (316bp), Fas
minus exon 6 (259bp) and b-actin (837bp) were separated
by electrophoresis on 3% agarose gels and stained with
ethidium bromide to visualize bands. PCR products were
excised from the gel, cloned and sequenced (Retrogen,
San Diego, CA, USA). An additional PCR reaction was
performed with the same forward primer but the
reverse primer spanned the Exon5–Exon7 junction
(50-CTTCCTTTCTCTTCACTTCC-30). This set of pri-
mers will amplify a 110-bp product only if splicing is
redirected to skip Exon6.
RESULTS
Designof aprototype RNA Lasso
The sequence and secondary structure of a prototype
Lasso, ATR1, is shown in Figure 1a. ATR1 contains
three functional elements: an HPR sequence with its sub-
strate sequences at both ends, an antisense sequence (22-
nt) that can hybridize to the coding region of TNF-a to
form two turns of an A-form helix (27) and a sequence
that can bind to that duplex to form a triplex. The HPR
sequence was adapted from a previously described mini-
mal HPR construct, mini-M36 (19,28), by substituting the
TNF-speciﬁc antisense and triplex forming sequences for
the 36-nt sequence of loop 2. The triplex forming sequence
was included with the expectation that triplex formation
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its target RNA by placing the 30-end of the Lasso near its
50-end (Figure 1a). The target sequence for ATR1 was
chosen primarily because it contained an extensive poly-
pyrimidine tract favorable for triplex formation. Although
accessibility of this target site in the RNA targets used
was not speciﬁcally investigated, our results suggest that
ATR1 molecules bind eﬃciently with the corresponding
target sequences both in vitro and in cell lysates
(see below).
Self-processing ofLasso transcripts
Upon transcription in vitro, the unprocessed Lasso
precursor (UPL) undergoes HPR-catalyzed sequential,
intramolecular cleavage at its 50- and 30-ends, both of
which contain ribozyme cleavage/ligation sites
(Figure 2). The ﬁrst cleavage results in either a 50-o r3 0-
half-processed molecule (50-HPL and 30-HPL, respec-
tively), and the second cleavage yields a fully processed
linear Lasso (LL). LL can then undergo intramolecular
ligation, also catalyzed by the HPR, to produce the circu-
lar Lasso form (CL). The last step is reversible, and LL
and CL coexist in an equilibrium distribution. Similar self-
processing schemes have been described previously for
HPR derivatives (28–30).
In the case of ATR1, self-processing is only partially
completed upon its synthesis via in vitro transcription
in the presence of 6mM Mg
2+ (see Materials and
Methods section). Additional incubation in buﬀer
containing 50mM Tris–HCl (pH 7.5) and 10mM MgCl2
(TM buﬀer) enables completion of self-processing
(Figure 3a, lanes 1 and 6). By comparing the electro-
phoretic mobilities and analyzing the 50- and 30-ends
of each Lasso species (see below), we assigned electro-
phoretic bands for the following processing products
of [ATR 1]: UPL (136nt), 50-HPL (128nt) and 30-HPL
(127nt), LL and CL (both 117nt).
Several lines of evidence support the identiﬁcation of
the slowest migrating band as the circular RNA species.
First, the lower electrophoretic mobility of CL in compar-
ison to LL is consistent with the properties of circular
RNAs longer than 42nt, which migrate more slowly
than their linear counterparts (22,28). Second, incubation
of gel-puriﬁed CL and LL bands in buﬀer that supports
HPR catalytic activity showed that these bands intercon-
vert only with each other (Figure 3a, lanes 2–5). The
assignments of CL and LL were further supported by
32P-end-labeling analysis (29). CL could not be labeled
by [
32P]pCp and T4 RNA ligase at its 30-end (Figure 3a,
lane 7), or by [g
32P]ATP and T4 polynucleotide kinase
at its 50-OH end (Figure 3a, lane 8), consistent with CL
being a circular molecule without free ends. LL could
not be labeled at the 30-end, consistent with its having
a2 0,30-cyclic phosphate, but it could be 50-end kinased
(see Figure 3a, lanes 7–8), consistent with its having a
50-OH. The only bands that could be 30-end-labeled were
UPL and 50-HPL (Figure 3a, lanes 7), conﬁrming that they
have free 30-OH groups as expected. Speciﬁc
32P-labeling
of 50-HPL and LL at their 50-ends (Figure 3a, lane 8)
established that these are the only species containing
a free 50-OH. Additional conﬁrmation of the circular
nature of CL was provided by partial RNA cleavage of
32P-labeled CL under mild alkaline conditions (23). Under
these conditions, the internally
32P-labeled CL produced a
band comigrating with LL, with no intermediate bands
appearing between the putative circular and linear RNA
species (data not shown). This pattern is expected of a
circular nucleic acid since a single alkali-induced cleavage
will produce a linear RNA with the same length and elec-
trophoretic mobility as LL.
Figure 1. Structures of the TNF-speciﬁc RNA Lassos ATR1 (a) and ALR 562-2 (b). The top structures correspond to unprocessed lasso transcripts
(pre-Lasso), while the bottom structures depict fully processed lassos circularized around the murine TNF-a target RNA. Antisense sequences within
the Lassos are shown in red, hairpin ribozyme sequences are in black, linker sequences are in blue, the U25!C25 substitution is in green, and target
RNA is purple. The ribozyme cleavage/ligation sites are marked by arrows. Potential base pairing of a triplex strand is indicated by black dots.
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Binding of Lasso ATR1 with target TNF685, a 685-nt
fragment of TNF-a mRNA containing the target of the
ATR1 antisense sequence (nt 562–583 of the full-length
mRNA) was performed in solutions supporting HPR cat-
alysis. Complex formation was analyzed by gel mobility
shift assays under both nondenaturing (data not shown)
and denaturing conditions (Figure 3b and c). We found
that Lasso-target complexes were stable under both con-
ditions. d-PAGE was adopted as the standard method for
analyzing these strong complexes. We conﬁrmed that the
mobility shifts of the Lasso-target complexes were the
same whether the Lassos or the targets were radio-labeled
(labeling was by transcription in the presence of [a-
32P]-
CTP). In time-course experiments, complex formation was
50% complete in 1min (t1/2) and 95% complete within
10min (Figure 3b).
Products of self-processing of the ATR1 form two dif-
ferently shifted complexes with TNF685 (Figure 3c, lanes
1–2). To identify them and compare their relative thermo-
stability, these complexes were additionally incubated
(post-incubated) at increasing temperatures after complex
formation at 378C and analyzed by d-PAGE. After post-
incubation at 508C, virtually all ATR1 species were shifted
into one or the other of the two complexes (Figure 3c,
lanes 2–3). However, after post-incubation at 658C, the
lower shifted complex remained intact while the upper
one dissociated, and bands that comigrated only with
the linear Lasso species (LL and HPL) reappeared
(Figure 3c, compare lanes 1 and 4). After post-incubation
at 808C, the lower shifted complex also dissociated, and
a band comigrating with the free circular (CL) Lasso
appeared (Figure 3c, lanes 5–6). We interpret from these
results that the faster migrating complex band was CL
Figure 2. Schematic of self-processing (cleavage and ligation) of the RNA Lasso precursor. Self-processing of a primary Lasso transcript (pre-Lasso)
having 50-triphosphate (50-PPP) and 30-hydroxyl (30-OH) groups can proceed by either the right or left pathway. Self-cleavage catalyzed by the HPR
generates speciﬁc fragments having 20,30-cyclic phosphate (20,30 >P) and 50-hydroxyl (50-OH) termini. The fully 50- and 30-processed RNA Lasso exists
as an equilibrium between circular and linear forms. The cleavage/ligation sites are marked by magenta arrows with asterisks. Loops 1, 2 or 3
indicated in the bottom structure can be used for insertion of an antisense sequence. Here, the antisense sequence (red) is inserted into loop 2 (blue).
Species are identiﬁed as unprocessed Lasso (UPL), 50-half-processed Lasso (50-HPL), 30-half-processed Lasso (30-HPL), 50- and 30-processed ‘linear’
Lasso (LL) and circular Lasso (CL).
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complex band corresponded to LL bound to target
RNA. Therefore, the circular Lasso-target complex
appeared to be more thermostable than the linear Lasso-
target complexes.
We found that even linear Lassos can form com-
plexes that are more stable than ordinary RNA–RNA
duplexes. In chase experiments, we used 20-nt sense or
antisense synthetic RNAs that correspond to the TNF-a
target site. We observed that even a 7- to 14-fold excess
of these short RNAs could not displace the TNF-speciﬁc
Lassos from long TNF RNA targets when incubated with
the preformed Lasso-target complexes (Supplementary
Figure 1).
In negative control experiments, no complex formation
was observed between TNF685 target and mini-M36
(19,28), which contains the HPR portion of the Lasso
but lacks sequence complementary to the TNF target
(data not shown). In addition, complexes between ATR1
and unrelated target RNAs that did not contain the ATR1
binding site were not detected even by nondenaturing
PAGE (data not shown). As expected, cleavage of the
RNA targets in trans by the Lasso-HPR domain were
not observed.
Circular Lassos bindtarget RNAs vialinear intermediates
Sterically, it should not be a topological problem for
linear Lasso species to hybridize with a target RNA and
then circularize around it. But, how can a circular Lasso
species bind to the linear RNA target and circularize
around it? To address this question, we incubated
32P-labeled ATR1 transcripts with excess target TNF685
in two diﬀerent solutions: (i) TM buﬀer containing 10mM
Figure 3. Transcription, self-processing, and target binding of Lasso ATR1. (a) Lane 1 shows internally
32P-labeled products of ATR1 transcription
and spontaneous self-processing during the transcription reaction. Lane 2 shows gel-puriﬁed LL (linear Lasso), and lane 3 its partial conversion to
CL (circular Lasso) through self-ligation after incubation in TM buﬀer (50mM Tris–HCl, 10mM MgCl2) for 1h at 378C. Lane 4 shows gel-puriﬁed
CL, and lane 5 its partial conversion to LL through self-cleavage after the same incubation as for lanes 2 and 3. Lanes 6–8 compare internally
32P-labeled ATR1 Lasso species (lane 6, the same as lane 1) with 30-end-labeled (lane 7) and 50-end labeled ATR1 (lane 8). Because of eﬃcient Lasso
self-processing, the unprocessed Lasso (UPL) and the half-processed Lasso (comigrating 50-HPL and 30-HPL) forms are present in relatively small
amounts (lanes 1 and 6). (b) Time-course of binding of internally
32P-labeled TNF685 RNA target with an excess of non-radioactive Lasso ATR1
transcription mixture in TM buﬀer at 378C for the indicated time periods. (c) Internally
32P-labeled ATR1 incubated with or without an excess of
nonradioactive TNF685 fragment (as indicated) in TM buﬀer for 2h at 378C. Samples in lanes 3–6 were additionally incubated for 2min at elevated
temperatures as indicated and transferred immediately to ice to prevent rehybridization of the complexes. The products were analyzed by electro-
phoresis on denaturing 6% polyacrylamide gels (d-PAGE).
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2+ (+Mg), in which the CL and LL Lasso species are
able to interconvert, or (ii) buﬀer containing 10mM
EDTA and no added Mg
2+ ( Mg), in which LL cannot
circularize and CL cannot interconvert into LL because
the HPR is inactive under these conditions (Figure 4).
Because the transcription reaction to synthesize ATR1
contains Mg
2+ ions, initial self-processing of the Lasso
RNA occurs during transcription. However, additional
incubation in +Mg buﬀer allows equilibration between
LL and CL. Under the +Mg conditions, both LL and
CL species bound to the target, and two distinct com-
plexes that correspond to the circular and linear Lasso-
target complexes were detected by d-PAGE (Figure 4a,
lanes 1–2). When these complexes were postincubated
under highly denaturing conditions (908C, 50% forma-
mide, 10mM EDTA) in which both CL and LL forms
can be displaced from the complexes but cannot intercon-
vert, both dissociated forms were detected (Figure 4a, lane
3). Under the  Mg conditions, the original ATR1 tran-
script did not undergo complete self-processing and the
LL form predominated over CL (Figure 4a, lane 4).
Under this condition, LL was completely shifted into the
corresponding complex, which dissociated only under
highly denaturing conditions (Figure 4a, lanes 5–6),
whereas the CL species, here present at low levels, did
not form a strong complex detectable by d-PAGE
(Figure 4a, lane 5). This discrimination is more obvious
when the gel is overexposed (data not shown). It is possi-
ble that less stable complexes between CL species and the
target could form in the absence of Mg
2+ but would then
dissociate (and therefore not be detected) under d-PAGE
conditions. These results suggest that, in the presence of
Mg
2+, circular Lasso species must convert to LL through
self-cleavage either before, or as result of, target binding
in order to form strong complexes. Once bound to the
target RNA, the linear Lasso can religate, circularizing
around the target as schematically depicted in Figure 4b.
The similar CL/LL ratios before and after ATR1 binding
to targets (Figure 4a, lanes 1 and 3) show that this Lasso
can circularize around a target as eﬃciently as it circu-
larizes in the absence of target.
The triplex-forming domainis notrequired forLasso
circularization aroundthe target
To study if the triplex-forming domain present in ATR1
is required for circularization of the Lasso around the
target, we prepared Lasso ALR-562-2, which lacked the
triplex-forming sequence of ATR1 but had the same
antisense sequence (compare Figure 1a and b). In ALR-
562-2, the antisense sequence was moved further
from the HPR cleavage/ligation site than in ATR1 and
a linker was substituted for the triplex-forming
Figure 4. Binding of circular and linear ATR1 forms to TNF RNA target depends on presence of Mg
2+.( a) Internally
32P-labeled ATR1 transcripts
incubated at 378C for 2h in TM buﬀer containing 10mM MgCl2 (lanes 1–3) or in buﬀer containing 10mM EDTA (lanes 4–6) either without target
(lanes 1 and 4) or in the presence of nonradioactive TNF685 target (lanes 2–3 and 5–6). Samples in lanes 3 and 6 were additionally postincubated at
908C for 2min to dissociate the Lasso-target complexes. The products were analyzed by 6% d-PAGE. (b) Schematic of the mechanism of formation
of complexes between Lasso (with antisense region shown in red) and target RNA (blue) under  Mg (top) and +Mg (bottom) conditions.
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The (AAC)8 sequence of the linker was chosen to mini-
mize formation of secondary structures that could aﬀect
HPR folding. The HPR domain in ALR562-2 was also
modiﬁed to stabilize the catalytically active structure of
HPR. These HPR modiﬁcations, which have been
described previously (31), included a U!C substitution
at position 25 in the ribozyme core, extension of the
substrate stem H1 by one G–C base pair, and sub-
stitution of a GNRA-type tetraloop for the 3-nt H4
terminal loop.
Products of ALR562-2 transcription and its self-
processing were characterized by the same methods as
with ATR1 (data not shown). The 50-HPL species was
identiﬁed as the major product of ALR562-2 formed
during transcription in the presence of 6mM Mg
2+,
whereas additional incubation in the TM buﬀer yielded
mostly the fully processed LL species (Figure 5a, lanes
1–2). When internally labeled LL was incubated with an
excess of target TNF685 in TM–formamide buﬀer, a high
yield of a strong Lasso-target complex was detected by
d-PAGE (Figure 5a, lane 3). However, the kinetics of
ALR562-2 binding to TNF685 were found to be about
10-fold slower than with ATR1 under similar conditions
(data not shown). When the ALR562-2 complex with
TNF685 was postincubated under highly denaturing con-
ditions (908C, 50% formamide, 10mM EDTA), the dis-
placed Lassos were mostly the circular form (Figure 5a,
lane 4), whereas ALR562-2 that had not been exposed
to the target was predominantly in the linear form
(Figure 5a, lane 2). Therefore, the triplex-forming
domain present in ATR1 is not required for Lasso circu-
larization on the target but may promote hybridization
since ATR1 does binds to target with faster kinetics
than the non-triplex containing ALR562-2.
Theoretically, the triplex-forming strand of ATR1 could
form ﬁve U A-U and six C
+ G-C Hoogsteen base-
triplets, whose formation typically requires mildly
acidic conditions to have a protonated cytosine (32).
In addition, there are ﬁve potential A U-A and four
Figure 5. Lasso ALR562-2 binding to linear TNF685 and a circular target (CMT). (a) Products of self-processing of internally
32P-labeled ALR562-2
in transcription buﬀer containing 6mM Mg
2+ (lane 1) and in buﬀer containing 50mM Tris–HCl, 10mM MgCl2, 20% formamide (lane 2). Lane 3:
formation of the strong complex between ALR562-2 (from lane 2) and nonradioactive TNF685 target provided in excess. Lane 4: products of
dissociation of the complex from Lane 3 upon addition of 50% formamide and 10mM EDTA and post-incubation for 2min at 908C. The products
were analyzed by 6% d-PAGE and bands were assigned to Lasso-target complexes as well as unbound circular (CL), unprocessed (UPL), half-
processed (HPL) and linear (LL) Lasso forms as indicated. (b) Demonstration of topological linkage between CMT and Lasso ALR562-2. Internally
32P-labeled Lasso ALR562-2 was incubated in TM–formamide buﬀer containing 50mM Tris–HCl (pH 7.5), 10mM MgCl2, 20% formamide (lanes 1–
3) or 50mM Tris–HCl (pH 7.5), 10mM EDTA, 20% formamide (lanes 4–6) for 2h at 378C either alone (lanes 1 and 4) or with the CMT target
(lanes 2–3 and 5–6). Samples in lanes 3 and 6 were additionally postincubated at 958C for 5min followed by quenching on ice. The products were
analyzed by denaturing 6% PAGE and assigned to complexes of CMT with various forms of the Lasso (HPL-CMT, LL-CMT and CL-CMT) as well
as unbound circular (CL), unprocessed (UPL), half-processed (50-HPL and 30-HPL) and linear (LL) forms as indicated.
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is pH-independent although sterically constrained
because the major groove of a typical RNA duplex is
not wide enough to accommodate the third strand
(33,34). We found that formation of strong complexes
between ATR1 and the TNF target increased when the
pH was changed from 5.2 to 8.0, while the equilibrium
between the circular and linear Lasso forms was not
pH-dependent (see Supplementary Figure 2). Because
ATR1 circularized around the target more eﬃciently at
pH>6.5 than at pH<6, if an ATR1-target RNA
triplex structure is formed, it appears to hinder rather
than promote circularization of the Lasso bound to
target RNA.
Lassos can form true topologically linked complexes
To verify that circular Lassos are truly intertwined with
the target RNA in their strong complexes, we examined
the binding of Lasso ALR562-2 with a CMT, which was
prepared by circularization of a corresponding linear
form (LMT) (see Supplementary Figure 3). These two
targets CMT and LMT, each 120nt in length, contain
the 22-nt TNF sequence ﬂanked by two (AAC)8 linkers
and a hairpin-forming element that facilitates LMT circu-
larization by RNA ligase (21).
The partially and fully self-processed forms of
32P-labeled ALR562-2, which were primarily the 50-HPL
and LL forms, were incubated with an excess of CMT,
either (i) in buﬀer containing 10mM Mg
2+ (+Mg), in
which case the 50-HPL was completely converted into
LL form while LL and CL forms were able to interconvert
(Figure 5b, lanes 1–3), or (ii) in buﬀer containing 10mM
EDTA and no added Mg
2+ ( Mg), in which case the
ribozyme was inactive, 50-HPL could not be converted
into the LL form, and no CL could be formed from LL
(Figure 5b, lanes 4–6). All Lasso species bound CMT and
were retarded upon denaturing polyacrylamide gel electro-
phoresis. Under the +Mg conditions, three discrete bands
corresponding to diﬀerent forms of Lasso-target com-
plexes were detected (Figure 5b, lane 2), whereas under
the  Mg conditions, only one major complex band was
observed (Figure 5b, lane 5). The identity of each complex
was assigned by analyzing the Lasso dissociation products
after post-incubation of these complexes under highly
denaturing  Mg conditions (908C, 50% formamide,
10mM EDTA). We reasoned that under highly denatur-
ing conditions all nontopologically linked complexes
between Lasso and CMT should dissociate and free
Lasso species should re-appear on d-PAGE. Indeed, we
found that all Lasso-CMT complexes formed in the
absence of free Mg
2+ dissociated under highly denaturing
conditions, and the major labeled species released was 50-
HPL, as expected (Figure 5b, lane 6). Thus, we assigned
the major band (Figure 5b, lane 5) to the complex of CMT
with 50-HPL. This band also corresponds to the top-
shifted, minor band in Figure 5b, lane 2. When Lasso–
CMT complexes that formed in the presence of Mg
2+
were postincubated at 908C, the two uppermost gel-shifted
bands disappeared, and the LL and 50-HPL forms of the
Lassos reappeared (compare Figure 5b, lanes 2 and 3). We
assigned the middle shifted band (Figure 5b, lane 2) to the
CMT complex with LL and the bottom-shifted band to
the complex with CL, which survived the highly denatur-
ing conditions. Since the CL species did not reappear upon
incubation at 908C (Figure 5b, lane 3) as was the case with
the linear target, we concluded that the only surviving
band represented a true topologically linked complex
between circular Lasso and circular target RNA. In sub-
sequent experiments, we conﬁrmed that this complex did
not dissociate even after incubation at 958C for 10min
(data not shown). The minor shifted bands that appeared
in lanes 3 and 6 (Figure 5b) presumably result from partial
rehybridization, which may occur during the loading of
samples on the gel. In control experiments with the
linear target LMT, we did not observe any
complexes that could survive the highly denaturing con-
ditions (data not shown).
Lassos can blocktranslation efficiently in vitro
Having demonstrated that Lassos are able to bind rapidly
to and form strong complexes with model RNA targets,
we tested whether the Lasso ATR1 would be able to block
expression of a model mRNA via an in vitro translation
assay. This model mRNA, TNF22-Luc, contained the
22-nt TNF sequence that was the target of ATR1 placed
upstream of the luciferase gene (Figure 6a). ATR1
was added in increasing amounts to equimolar mixtures
of TNF22-Luc and pro-IL-1b mRNAs (a nonspeciﬁc
control RNA). Following a 40min incubation with a
Figure 6. Inhibition of in vitro translation of a TNF-luciferase reporter
mRNA by Lasso ATR1. (a) Schematic of TNF22-luc. (b) Products of
translation of TNF22-Luc mRNA and pro-IL-1 mRNA (negative con-
trol) in rabbit reticulocyte lysate in the presence increasing amounts of
Lasso ATR1 and
35S-labeled methionine. Lane 1 contains only the
TNF22-Luc mRNA RNA, while lanes 2–6 contain both TNF22-Luc
and pro-IL-1 mRNAs. Lanes 3–6 additionally contain 20-, 40-, 80- and
160-fold molar excess of ATR1 Lasso with respect to the targets. The
translation products were analyzed by 12% SDS–PAGE.
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35S-labeled
methionine, the translation products were separated by
SDS–PAGE. At 20- and 40-fold excess of Lasso to
target RNA (Figure 6b, lanes 3 and 4), in vitro translation
was inhibited by 80 and 92%, respectively, with only a
modest reduction in expression of pro-IL-1b (16 and
26%, respectively).
We also demonstrated the superiority of Lasso ATR1,
which can circularize around the target, over an antisense
RNA that cannot not circularize (AT, derived from ATR1
by deleting the HPR domain), in the inhibition of target
RNA translation (see Supplementary Figure 4). In these
experiments, we used the same TNF22-Luc mRNA target
(Figure 6a) along with a negative control target, which
was the same sequence as TNF22-Luc but without the
TNF sequence targeted by ATR1 and AT. Transcription
of these constructs using T7 RNA polymerase produced
mRNAs that were then incubated with either ATR1 or
AT RNA and then provided as a template for
translation using the rabbit reticulocyte lysate system.
Luciferase activity assays revealed that, for an optimal
ATR1:target molar ratio of 30:1, Lasso ATR1 provided
>95% knockdown of translation of TNF22-Luc mRNA,
whereas antisense AT RNA reduced the eﬃcacy of trans-
lation only by about 5%.
RNA Lassos canredirect splicing ofFas pre-mRNA
To test for biological activity of Lassos, we decided to
evaluate their ability to alter splicing patterns by interfer-
ing with the splicing machinery at crucial mRNA
sequences. Speciﬁcally, we tried to skew Fas pre-RNA
splicing towards production of mRNA encoding soluble
Fas. To this end, we designed three anti-Fas Lassos (Fas1,
Fas2 and Fas3) targeting the Fas pre-mRNA intron
5/exon 6 boundary sequences as well upstream to the
splice branch point sequence (Figure 7a and Supplemen-
tary Figure 5). We conﬁrmed that the anti-Fas Lassos
have the ability to access the target sites and form
Figure 7. RNA Lassos can redirect splicing of Fas pre-mRNA. (a) Target sequences (red) of Lassos Fas1, Fas2 and Fas3 that span the intron 5/
exon 6 splice junction. (b) Schematic of intron/exon structure of Fas receptor primary transcript (not to scale). The Lasso target site (intron 5/exon 6
junction) chosen to prevent inclusion of exon 6 in the ﬁnal mRNA product is shown. The PCR primer site locations for analysis are shown as
horizontal arrows. (c) RT–PCR ampliﬁcation (using the exon 4 and exon 9 primers, black arrows) of products of Fas splicing in the presence of
Lassos Fas1, Fas2 or Fas3. No shorter DNA fragment corresponding to Fas lacking exon 6 was seen in the absence of Fas Lassos (ct). b-actin serves
as a loading control. Stds is a DNA ladder (100–1000 bp). (d) Conﬁrmation that Fas Lassos lead to exon 6 skipping revealed by PCR analysis using
a downstream primer spanning the exon 5 and exon 7 junction (red arrow) along with the exon 4 upstream primer, which are unable to amplify a
product that includes exon 6. Lanes 2–4 and 5–7 correspond to independent experiments with anti-Fas Lassos 1, 2 and 3. Control lane 8 corresponds
to the RT–PCR products obtained with cells that were not transfected by Lassos (ct), and lane 9 contains no PCR template (n/a).
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those described above. The eﬃciency (rate and yield) of
binding of the Fas-speciﬁc Lassos to Fas were found to be
moderate (data not shown) in comparison to those for
the TNF-speciﬁc Lassos with their target RNA, but we
decided to test the anti-Fas lassos in cells without further
in vitro optimization. We reasoned that a cellular envi-
ronment would provide diﬀerent Lasso-target binding
parameters that could not be predicted based only on
the in vitro tests.
Human Jurkat lymphocytes were transfected with the
anti-Fas Lassos as described in Materials and Methods
section. Total RNA and protein were isolated from the
cells in 24–48h after the transfection. The total RNA
was analyzed by RT-PCR using the speciﬁc primers
(Figure 7b). The resulting PCR-ampliﬁed DNA fragments
corresponding to full-length Fas (231bp) and Fas minus
exon 6 (169bp) were analyzed on agarose gels to deter-
mine the extent of redirection of splicing (Figure 7c).
To conﬁrm that transfection of the Jurkat cells with
anti-Fas Lassos results in redirection of Fas pre-mRNA
splicing such that exon 6 is excluded, an additional PCR
analysis was performed (Figure 7d). In two independent
transfection experiments, the 112-bp product lacking exon
6 was only observed following transfection with Lassos
directed against the intron 5/exon 6 splice junction.
Finally, this fragment was excised from the gel, puriﬁed,
cloned and sequenced. As expected, no exon 6 sequence
was found.
DISCUSSION
In this study, we have introduced a novel class of
antisense-based agents called RNA Lassos that contain
both HPR and antisense domains. In contrast to the con-
ventional use of ribozymes as sequence-speciﬁc nucleases
(15,35), RNA Lassos do not cleave their RNA targets.
Instead, RNA Lassos hybridize to and circularize
around them forming intertwined Lasso-target complexes.
Complexes with circular targets are topologically linked
and thus cannot be dissociated even under highly denatur-
ing conditions. Lasso complexes with linear RNA targets,
however, can be dissociated under highly denaturing con-
ditions although they were found to be more thermostable
than if they were simple antisense RNA–RNA duplexes
(Figure 3c). Higher thermostability has the potential for
higher potency in gene inhibition, as has been demon-
strated for chemically modiﬁed oligonucleotides such
as 20-OMe, N30-P50, morpholino phosphorodiamidates
and LNA, which also bind to their targets with high aﬃ-
nity (3–7).
The HPR, a naturally existing ribozyme, was chosen for
use in the Lasso design for several reasons, including its
catalytic activity (both in vitro and in vivo) as well as the
folded, stable structure of its catalytic domain (36,37). In
the presence of Mg
2+, the HPR catalyzes a reversible, site-
speciﬁc RNA cleavage and ligation reaction, generating
20,30-cyclic phosphate and 50-OH termini upon scission or
reformation of a 30–50 phosphodiester bond upon ligation
(36). Because HPR substrate sequences are incorporated
into both the 50- and 30-ends of the primary Lasso tran-
scripts, intramolecular cleavage reactions at each end
followed by ligation in cis result in a circular RNA mole-
cule. The size and sequence of the loops connecting the
HPR substrate and enzymatic domains can be modi-
ﬁed substantially without dramatic eﬀects on HPR cata-
lytic activity as long as the loop sequences do not prevent
the formation of catalytically active HPR structures
(28,38–40). Although the HPR is particularly well-suited
for this application, other ribozymes that combine both
cleavage and ligation activities could be evolved by
in vitro selection (41) and used in place of the HPR
in Lassos.
RNA Lassos bear some resemblance to DNA padlock
probes (42,43), which also circularize around polynucleo-
tide targets. However, the two diﬀer in important respects.
Padlock probes are 70–100nt ODNs whose ends can bind
to adjacent sites on a target nucleic acid in such a way that
they can be ligated. Ligation is accomplished by addition
of a DNA ligase and yields a circular padlock probe linked
to the target. In contrast, Lassos are RNAs of 120–130nt,
are generally made by transcription in vitro, and use an
internal HPR domain to self-process the ends of the pri-
mary Lasso transcripts. This reaction produces ends that,
using the same HPR activity, can reversibly circularize in a
nontarget-dependent manner with no need for an added
ligase. Unlike with padlock probes, the ends of the Lasso
are not bound to the polynucleotide target prior to liga-
tion. The ability to be transcribed allows Lassos to be
expressed from DNA vectors in vivo, whereupon they
can spontaneously self-process and self-circularize within
the cell. Padlock probes, on the other hand, must be pre-
pared by chemical synthesis and require careful puriﬁca-
tion to isolate products that can be ligated in a target-
dependent manner.
In our initial Lasso design, exempliﬁed by ATR1, we
included a triplex-forming sequence with the expectation
that this feature would promote Lasso circularization
around target RNA by guiding the 30-end of the Lasso
to fold back such that it would aid in bringing the ends
into close proximity for eﬃcient self-ligation (Figure 1a).
We found that both ATR1 and a variant (ALR562) that
lacked the triplex-forming element could circularize
around the same target (Figures 3c and 5a). We therefore
concluded that the triplex-forming domain was not
required for the Lasso to circularize around the target
RNA. Of the two Lasso designs, the simpler one lacking
the triplex-forming sequence is more versatile because
there is no requirement for the target region to have
the homopurine character needed for stable triplex forma-
tion. Comparison of the binding and circularization
properties of these two Lassos indicates that variations
in the sequences of both the HPR domain and the linkers
surrounding the antisense domain can aﬀect the rate of
target hybridization and the eﬃciency of self-ligation.
Interestingly, circularization of Lasso ALR562-2 is pro-
moted by binding to the target whereas circularization
of ATR1 is not. Although unintended, this result indicates
that target-dependent Lasso circularization can be
achieved in ways other than through triplex formation.
The study of such mechanisms will be published elsewhere
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Because of the modular nature of the RNA Lasso, it can
be modiﬁed easily to swap in antisense sequences for any
gene of interest. The sequence and length of the antisense
sequence can be varied to optimize the speciﬁcity of target
recognition as well as the rate of hybridization and yield of
complex. Antisense sequence lengths in the range 18–25nt
appear to be optimal for specifying a unique target
sequence within the genome while minimizing the forma-
tion of stable, partially mismatched duplexes at unin-
tended target sites (i.e. oﬀ-target eﬀects). However, if
one takes into account variations in the number of genes
expressed in speciﬁc tissues at a given time (44) as well as
estimates of the amount of mRNA sequences that are
thought to be inaccessible because of intramolecular
structure and intermolecular macromolecular interac-
tions (45), as little as 14nt may be suﬃcient to confer
speciﬁcity.
We have demonstrated that both linear and circular
Lasso species can eﬃciently hybridize to and circular-
ize around target RNAs (Figures 3 and 4). Under target-
binding conditions, fully processed Lasso molecules exist
as interconverting linear and circular forms like any HPR
derivatives. The structures of the linear and circular forms
are probably similarly folded except that in the linear
form, the 50- and 30-termini are not covalently linked
(see bottom structures in Figure 2). We speculate that
this interaction provides Lassos with an inherent poten-
tial to be more sequence speciﬁc than ordinary antisense
RNA based on two factors. One factor is their circularity:
circular antisense DNAs are known to provide greater
sequence selectivity (i.e. less tolerance for mismatches)
than corresponding linear molecules (46–48). The other
factor is the presence of a stringency element, a feature
also shared with molecular beacons. Like a DNA molecu-
lar beacon (49), the Lasso cannot fully pair with a target
without disrupting its own structure. It ﬁrst interacts with
a target through formation of a few base pairs, but to fully
pair its antisense sequence, its termini must unfold, dis-
rupting intramolecular pairing interactions, to allow
extension of the target-antisense helix. It can then refold
into the ‘circular’ conformation where the termini are
adjacent to each other. Based on this model, we would
expect the speciﬁcity of any given Lasso to be inﬂuenced
by its GC-content as well as the accessibility of its target
sequence since internal structure in targets as well as
the antisense molecule can act as a stringency element.
A study on how Lasso sequence manipulations aﬀect
their sequence speciﬁcity will be described elsewhere
(A. Dallas, B.H. Johnston, and S.A. Kazakov, manuscript
in preparation).
There is now clear evidence of the in vivo eﬃcacy
of RNA-based drugs, both synthetic and vector expres-
sed (50). Lassos can be generated by either in vitro tran-
scription or in vivo expression from vectors. Like other
circular RNA molecules (23,51,52), Lassos should be
more stable in biological ﬂuids than linear RNAs since
circularization prevents RNA digestion by exonucleases.
Circularizable antisense molecules could also provide
more potent knockdown of cellular targets than linear
ones because of the enhanced thermostability of their
complexes with targets (42,53).
In this study, we demonstrated that expression of a
TNF22-Luc reporter construct could be blocked eﬃ-
ciently and sequence speciﬁcally by Lasso RNAs in a
model in vitro translation assay. Similar luciferase fusion
constructs have been previously used for screening of large
numbers of antisense agents, both in cell lysates and in
cells. The inhibitory proﬁles obtained for such gene sur-
rogates were usually found to be similar to those observed
in the corresponding endogenous genes assayed at the
mRNA level (54). For our studies, we used murine
TNF-a as a model target RNA, as the human form of
this cytokine has been validated as a therapeutic target
for treatment of chronic inﬂammation associated with
many diseases, including rheumatoid arthritis, psoriasis
and HCV-related liver necrosis (55). Since the target in
the TNF22-Luc reporter is upstream of the AUG start
codon, we speculate that the mechanism of translation
inhibition is steric interference with the formation of
the initiation complex or ribosome scanning.
Another possible application of the Lasso is to regulate
alternative splicing. In this work we demonstrated the
modest ability of several Lassos to redirect splicing of
Fas-pre-mRNA. Many tumor cells express Fas ligand as
a way to kill Fas-expressing tumor-inﬁltrating lym-
phocytes (TILs). The interaction between Fas and Fas
ligand, which results in apoptosis of TILs, is an increas-
ingly attractive cancer therapeutic target (26,56). The abil-
ity to redirect splicing could allow skipping of an exon of
Fas that is responsible for membrane anchoring, resulting
in a soluble receptor that cannot transduce signal. Thus,
not only is the receptor downregulated, resulting in unre-
sponsiveness of the aﬀected cells, but secretion of the solu-
ble receptor that is the new splicing product results in
binding and inactivation of extracellular ligand with the
result that neighboring cells are also protected.
The eﬃcacy of anti-Fas Lassos described in this work
was less than those provided by alternative antisense
approaches using synthetic morpholino oligonucleo-
tides (57–59). It remains to be seen to what extent this
eﬃcacy can be improved by selecting better target
sequences and adjusting the design of the Lasso. It is
well known that, on average, <5% of tested antisense
agents yield high potency in cells (60–62). Randomization
of certain sequences in Lassos together with in vitro selec-
tion methods can identify more potent Lasso molecules
(unpublished results).
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